ClariVest Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

ClariVest Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-73,967	Closed	-$1.18M	–	866
2024 Q1	$1.18M	Buy	73,967 +138	+0.2%	+$2.08K	0.12%	236
2023 Q4	$1.24M	Sell	73,829 -13,268	-15%	-$181K	0.07%	212
2023 Q3	$1.02M	Hold	87,097	–	–	0.06%	234
2023 Q2	$1.17M	Buy	87,097 +15,770	+22%	+$227K	0.06%	215
2023 Q1	$1.18M	Sell	71,327 -73	-0.1%	-$1.2K	0.05%	260
2022 Q4	$1.33M	Sell	71,400 -1,000	-1%	-$15.4K	0.06%	236
2022 Q3	$929K	Hold	72,400	–	–	0.04%	268
2022 Q2	$507K	Hold	72,400	–	–	0.02%	374
2022 Q1	$601K	Buy	+72,400	New	+$512K	0.02%	357
2021 Q2	–	Sell	-137,400	Closed	-$634K	–	764
2021 Q1	$634K	Buy	137,400 +7,600	+6%	+$30.2K	0.02%	376
2020 Q4	$434K	Sell	129,800 -1,800	-1%	-$6.05K	0.01%	405
2020 Q3	$391K	Sell	131,600 -8,000	-6%	-$31.3K	0.01%	382
2020 Q2	$645K	Sell	139,600 -8,100	-5%	-$36.4K	0.02%	366
2020 Q1	$569K	Sell	147,700 -9,300	-6%	-$38.2K	0.02%	388
2019 Q4	$588K	Sell	157,000 -1,700	-1%	-$7.95K	0.01%	412
2019 Q3	$843K	Hold	158,700	–	–	0.02%	363
2019 Q2	$610K	Buy	+158,700	New	+$686K	0.01%	350

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClariVest Asset Management's CPRX Position: Q2 2024 in Review

ClariVest Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 73,967 shares — an estimated $1.18M sold.

ClariVest Asset Management first reported a position in CPRX in Q2 2019 and held it in 17 quarters. The position peaked at $1.33M in Q4 2022. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

ClariVest Asset Management reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
ClariVest Asset Management sold 73,967 Catalyst Pharmaceutical shares in Q2 2024, an estimated $1.18M.
ClariVest Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2019 and held it in 17 quarters.
ClariVest Asset Management's Catalyst Pharmaceutical position peaked at $1.33M in Q4 2022.
271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on ClariVest Asset Management's 13F filing for Q2 2024, filed 7 Aug 2024.